113 related articles for article (PubMed ID: 1531601)
1. The cost of developing new drugs.
Oncology (Williston Park); 1992 Jan; 6(1):142-3. PubMed ID: 1531601
[No Abstract] [Full Text] [Related]
2. Drugs firms inflate research costs, watchdog says.
Knight J
Nature; 2001 Aug; 412(6847):571. PubMed ID: 11493879
[No Abstract] [Full Text] [Related]
3. What does R&D really cost?
Huff B
GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
[No Abstract] [Full Text] [Related]
4. The real cost of development.
GMHC Treat Issues; 2001; 15(7-8):16. PubMed ID: 11548510
[No Abstract] [Full Text] [Related]
5. Rising costs hold up drug discovery.
Miller HI
Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
[No Abstract] [Full Text] [Related]
6. The cost of developing imaging agents for routine clinical use.
Nunn AD
Invest Radiol; 2006 Mar; 41(3):206-12. PubMed ID: 16481902
[TBL] [Abstract][Full Text] [Related]
7. Cost of new drugs.
Goozner M
Health Aff (Millwood); 2005; 24(3):883-4; author reply 884-5. PubMed ID: 15886185
[No Abstract] [Full Text] [Related]
8. The price of pills. Does it really take $897 million for a new therapy?
Ezzell C
Sci Am; 2003 Jul; 289(1):25. PubMed ID: 12840941
[No Abstract] [Full Text] [Related]
9. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
10. [Now no new drugs will be developed!].
Lafolie P
Lakartidningen; 2006 Jan 25-31; 103(4):225. PubMed ID: 16491556
[No Abstract] [Full Text] [Related]
11. New estimates of drug development costs.
Frank RG
J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
[No Abstract] [Full Text] [Related]
12. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
13. The costs and economics of modern vaccine development.
Batson A
Dev Biol (Basel); 2002; 110():15-24. PubMed ID: 12477302
[No Abstract] [Full Text] [Related]
14. Opinion: development of new drugs is still a risky business.
Franks B
N J Med; 2002; 99(1-2):60, 59. PubMed ID: 15326736
[No Abstract] [Full Text] [Related]
15. Overcoming further challenges in the pharma/biotech industry: 2007 update.
Graul AI; Cruces E; Revel L; Serradell N; Rosa E
Drug News Perspect; 2008; 21(1):44-58. PubMed ID: 18301809
[TBL] [Abstract][Full Text] [Related]
16. 2 billion euro IMI launched with European pharma.
Hodgson J
Nat Biotechnol; 2008 Jul; 26(7):717-8. PubMed ID: 18612274
[No Abstract] [Full Text] [Related]
17. [Drug development in oncology. Its status and outlook with special consideration of the position of Germany].
Strohmeyer T; Weissbach L
Dtsch Med Wochenschr; 1999 Feb; 124(8):231-5. PubMed ID: 10093574
[No Abstract] [Full Text] [Related]
18. Goodbye Columbus! New NRDOs forego discovery.
Thiel KA
Nat Biotechnol; 2004 Sep; 22(9):1087-92. PubMed ID: 15340473
[No Abstract] [Full Text] [Related]
19. Research and development costs for drugs.
Riggs TL
Lancet; 2004 Jan; 363(9404):184. PubMed ID: 14738789
[No Abstract] [Full Text] [Related]
20. Payers growing influence on R&D decision making.
Hughes B
Nat Rev Drug Discov; 2008 Nov; 7(11):876-8. PubMed ID: 18974741
[No Abstract] [Full Text] [Related]
[Next] [New Search]
